Influence of peroxisome proliferator-activated receptor (PPAR)γ Plo12Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in Japanese

Tomomitsu Tahara, Tomiyasu Arisawa, Tomoyuki Shibata, Masakatsu Nakamura, Fangyu Wang, Naoko Maruyama, Yoshio Kamiya, Masahiko Nakamura, Hiroshi Fujita, Mitsuo Nagasaka, Masami Iwata, Kazuya Takahama, Makoto Watanabe, Ichiro Hirata, Hiroshi Nakano

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Activation of peroxisome proliferator-activated receptor γ (PPARγ) has been shown to inhibit the proliferation of gastric cancer cells. A common polymorphism at codon 12 of this gene (Pro12Ala) has been shown to confer protection against diabetes and colorectal cancer. We investigated the influence of PPARγ gene Plo12Ala polymorphism on the risk of gastric cancer and on the severity of Helicobacter pylori-induced gastritis as well as impaired fasting glucose (IFG) in Japanese. About 215 patients with gastric cancer (GC) and 201 patients without GC enrolled in this study. Plo12Ala polymorphism of PPARγ was investigated by PCR-RFLP in all of the subjects. The gastritis score of noncancerous antral mucosa was calculated by the updated Sydney system. The diagnosis of IFG was based on repeated evidence of serum fasting glucose (SFG) concentration of greater than or equal to 110 mg/dl. The Plo12Ala genotype of PPARγ showed a significantly higher frequency in GC patients than in controls (OR = 2.43; 95%CI = 1.04-5.67). In contrast, the Plo12Ala genotype held a lower risk of IFG (OR = 0.33; 95%CI = 0.13-0.83). The same genotype was associated with an increased risk of non-cardiac gastric cancer (OR = 2.39; 95%CI = 1.02-5.65), lower third gastric cancer (OR = 3.56; 95%CI = 1.31-9.71), advanced cancer (OR = 2.93; 95%CI = 1.13-7.58), and Lauren's intestinal cancer (OR = 2.94; 95%CI = 1.13-7.66). Among 151 gastric cancer subjects, the atrophy and metaplasia scores of the antral mucosa adjacent to cancer showed a tendency to be higher in those with the12Ala allele. Our study suggests that the PPARγ Pro12Ala polymorphism may be a shared risk marker of both IFG and gastric cancer in Japanese.

Original languageEnglish
Pages (from-to)614-621
Number of pages8
JournalDigestive Diseases and Sciences
Volume53
Issue number3
DOIs
Publication statusPublished - 01-03-2008

Fingerprint

Peroxisome Proliferator-Activated Receptors
Stomach Neoplasms
Fasting
Glucose
Genotype
Gastritis
Mucous Membrane
Intestinal Neoplasms
Metaplasia
Helicobacter pylori
Codon
Restriction Fragment Length Polymorphisms
Genes
Atrophy
Colorectal Neoplasms
Neoplasms
Alleles
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this

Tahara, Tomomitsu ; Arisawa, Tomiyasu ; Shibata, Tomoyuki ; Nakamura, Masakatsu ; Wang, Fangyu ; Maruyama, Naoko ; Kamiya, Yoshio ; Nakamura, Masahiko ; Fujita, Hiroshi ; Nagasaka, Mitsuo ; Iwata, Masami ; Takahama, Kazuya ; Watanabe, Makoto ; Hirata, Ichiro ; Nakano, Hiroshi. / Influence of peroxisome proliferator-activated receptor (PPAR)γ Plo12Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in Japanese. In: Digestive Diseases and Sciences. 2008 ; Vol. 53, No. 3. pp. 614-621.
@article{6496e35276fd4b959cf0b5fe0c11e933,
title = "Influence of peroxisome proliferator-activated receptor (PPAR)γ Plo12Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in Japanese",
abstract = "Activation of peroxisome proliferator-activated receptor γ (PPARγ) has been shown to inhibit the proliferation of gastric cancer cells. A common polymorphism at codon 12 of this gene (Pro12Ala) has been shown to confer protection against diabetes and colorectal cancer. We investigated the influence of PPARγ gene Plo12Ala polymorphism on the risk of gastric cancer and on the severity of Helicobacter pylori-induced gastritis as well as impaired fasting glucose (IFG) in Japanese. About 215 patients with gastric cancer (GC) and 201 patients without GC enrolled in this study. Plo12Ala polymorphism of PPARγ was investigated by PCR-RFLP in all of the subjects. The gastritis score of noncancerous antral mucosa was calculated by the updated Sydney system. The diagnosis of IFG was based on repeated evidence of serum fasting glucose (SFG) concentration of greater than or equal to 110 mg/dl. The Plo12Ala genotype of PPARγ showed a significantly higher frequency in GC patients than in controls (OR = 2.43; 95{\%}CI = 1.04-5.67). In contrast, the Plo12Ala genotype held a lower risk of IFG (OR = 0.33; 95{\%}CI = 0.13-0.83). The same genotype was associated with an increased risk of non-cardiac gastric cancer (OR = 2.39; 95{\%}CI = 1.02-5.65), lower third gastric cancer (OR = 3.56; 95{\%}CI = 1.31-9.71), advanced cancer (OR = 2.93; 95{\%}CI = 1.13-7.58), and Lauren's intestinal cancer (OR = 2.94; 95{\%}CI = 1.13-7.66). Among 151 gastric cancer subjects, the atrophy and metaplasia scores of the antral mucosa adjacent to cancer showed a tendency to be higher in those with the12Ala allele. Our study suggests that the PPARγ Pro12Ala polymorphism may be a shared risk marker of both IFG and gastric cancer in Japanese.",
author = "Tomomitsu Tahara and Tomiyasu Arisawa and Tomoyuki Shibata and Masakatsu Nakamura and Fangyu Wang and Naoko Maruyama and Yoshio Kamiya and Masahiko Nakamura and Hiroshi Fujita and Mitsuo Nagasaka and Masami Iwata and Kazuya Takahama and Makoto Watanabe and Ichiro Hirata and Hiroshi Nakano",
year = "2008",
month = "3",
day = "1",
doi = "10.1007/s10620-007-9944-8",
language = "English",
volume = "53",
pages = "614--621",
journal = "American Journal of Digestive Diseases",
issn = "0002-9211",
publisher = "Springer New York",
number = "3",

}

Tahara, T, Arisawa, T, Shibata, T, Nakamura, M, Wang, F, Maruyama, N, Kamiya, Y, Nakamura, M, Fujita, H, Nagasaka, M, Iwata, M, Takahama, K, Watanabe, M, Hirata, I & Nakano, H 2008, 'Influence of peroxisome proliferator-activated receptor (PPAR)γ Plo12Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in Japanese', Digestive Diseases and Sciences, vol. 53, no. 3, pp. 614-621. https://doi.org/10.1007/s10620-007-9944-8

Influence of peroxisome proliferator-activated receptor (PPAR)γ Plo12Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in Japanese. / Tahara, Tomomitsu; Arisawa, Tomiyasu; Shibata, Tomoyuki; Nakamura, Masakatsu; Wang, Fangyu; Maruyama, Naoko; Kamiya, Yoshio; Nakamura, Masahiko; Fujita, Hiroshi; Nagasaka, Mitsuo; Iwata, Masami; Takahama, Kazuya; Watanabe, Makoto; Hirata, Ichiro; Nakano, Hiroshi.

In: Digestive Diseases and Sciences, Vol. 53, No. 3, 01.03.2008, p. 614-621.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Influence of peroxisome proliferator-activated receptor (PPAR)γ Plo12Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in Japanese

AU - Tahara, Tomomitsu

AU - Arisawa, Tomiyasu

AU - Shibata, Tomoyuki

AU - Nakamura, Masakatsu

AU - Wang, Fangyu

AU - Maruyama, Naoko

AU - Kamiya, Yoshio

AU - Nakamura, Masahiko

AU - Fujita, Hiroshi

AU - Nagasaka, Mitsuo

AU - Iwata, Masami

AU - Takahama, Kazuya

AU - Watanabe, Makoto

AU - Hirata, Ichiro

AU - Nakano, Hiroshi

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Activation of peroxisome proliferator-activated receptor γ (PPARγ) has been shown to inhibit the proliferation of gastric cancer cells. A common polymorphism at codon 12 of this gene (Pro12Ala) has been shown to confer protection against diabetes and colorectal cancer. We investigated the influence of PPARγ gene Plo12Ala polymorphism on the risk of gastric cancer and on the severity of Helicobacter pylori-induced gastritis as well as impaired fasting glucose (IFG) in Japanese. About 215 patients with gastric cancer (GC) and 201 patients without GC enrolled in this study. Plo12Ala polymorphism of PPARγ was investigated by PCR-RFLP in all of the subjects. The gastritis score of noncancerous antral mucosa was calculated by the updated Sydney system. The diagnosis of IFG was based on repeated evidence of serum fasting glucose (SFG) concentration of greater than or equal to 110 mg/dl. The Plo12Ala genotype of PPARγ showed a significantly higher frequency in GC patients than in controls (OR = 2.43; 95%CI = 1.04-5.67). In contrast, the Plo12Ala genotype held a lower risk of IFG (OR = 0.33; 95%CI = 0.13-0.83). The same genotype was associated with an increased risk of non-cardiac gastric cancer (OR = 2.39; 95%CI = 1.02-5.65), lower third gastric cancer (OR = 3.56; 95%CI = 1.31-9.71), advanced cancer (OR = 2.93; 95%CI = 1.13-7.58), and Lauren's intestinal cancer (OR = 2.94; 95%CI = 1.13-7.66). Among 151 gastric cancer subjects, the atrophy and metaplasia scores of the antral mucosa adjacent to cancer showed a tendency to be higher in those with the12Ala allele. Our study suggests that the PPARγ Pro12Ala polymorphism may be a shared risk marker of both IFG and gastric cancer in Japanese.

AB - Activation of peroxisome proliferator-activated receptor γ (PPARγ) has been shown to inhibit the proliferation of gastric cancer cells. A common polymorphism at codon 12 of this gene (Pro12Ala) has been shown to confer protection against diabetes and colorectal cancer. We investigated the influence of PPARγ gene Plo12Ala polymorphism on the risk of gastric cancer and on the severity of Helicobacter pylori-induced gastritis as well as impaired fasting glucose (IFG) in Japanese. About 215 patients with gastric cancer (GC) and 201 patients without GC enrolled in this study. Plo12Ala polymorphism of PPARγ was investigated by PCR-RFLP in all of the subjects. The gastritis score of noncancerous antral mucosa was calculated by the updated Sydney system. The diagnosis of IFG was based on repeated evidence of serum fasting glucose (SFG) concentration of greater than or equal to 110 mg/dl. The Plo12Ala genotype of PPARγ showed a significantly higher frequency in GC patients than in controls (OR = 2.43; 95%CI = 1.04-5.67). In contrast, the Plo12Ala genotype held a lower risk of IFG (OR = 0.33; 95%CI = 0.13-0.83). The same genotype was associated with an increased risk of non-cardiac gastric cancer (OR = 2.39; 95%CI = 1.02-5.65), lower third gastric cancer (OR = 3.56; 95%CI = 1.31-9.71), advanced cancer (OR = 2.93; 95%CI = 1.13-7.58), and Lauren's intestinal cancer (OR = 2.94; 95%CI = 1.13-7.66). Among 151 gastric cancer subjects, the atrophy and metaplasia scores of the antral mucosa adjacent to cancer showed a tendency to be higher in those with the12Ala allele. Our study suggests that the PPARγ Pro12Ala polymorphism may be a shared risk marker of both IFG and gastric cancer in Japanese.

UR - http://www.scopus.com/inward/record.url?scp=39849085359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39849085359&partnerID=8YFLogxK

U2 - 10.1007/s10620-007-9944-8

DO - 10.1007/s10620-007-9944-8

M3 - Article

C2 - 17763950

AN - SCOPUS:39849085359

VL - 53

SP - 614

EP - 621

JO - American Journal of Digestive Diseases

JF - American Journal of Digestive Diseases

SN - 0002-9211

IS - 3

ER -